A four-part digital event series with Harvard Medical School Executive Education and STAT News

The COVID-19 crisis is galvanizing rapid change in the health care industry, especially in provider organizations, tech and biopharma. New collaborations, regulatory and reimbursement changes, and novel applications of tech and biopharmaceutical platforms have created new strategies and opportunities.

What does this new way of doing business in health care mean for the COVID-19 pandemic and plans to re-open society? What aspects of our crisis footing will persist and shape our ‘new normal’ in health care?

President, Novartis Institutes for BioMedical Research (NIBR)
Executive Committee Member, Novartis
VP of Virtual Care, Partners Healthcare Digital Health
Director, MGH Center for Telehealth
Executive Vice Chairman, Department of Neurology, Massachusetts General Hospital
Chief Innovation Officer, Boston Children’s Hospital
Professor of Pediatrics, Harvard Medical School
President, ORRA Group, LLC and Associate Clinical Professor of Medicine, University of Colorado School of Medicine